Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 12 sources cited
Key Takeaways
- Bupropion is an antidepressant FDA-approved for depression and smoking cessation. It causes modest weight loss as a side effect, averaging 2 to 5 kg over 6 to 12 months at antidepressant doses.
- Combined with low-dose naltrexone (the brand Contrave), bupropion is FDA-approved for chronic weight management. The combination produces about 5 to 6% weight loss at one year.
- Bupropion alone is not FDA-approved for weight loss but is sometimes prescribed off-label, especially for patients with depression and obesity together.
- The most common side effects are insomnia, dry mouth, and headache. The most serious risk is seizure, which is rare at recommended doses.
- GLP-1 medications produce more weight loss (5 to 22%) than bupropion or bupropion-naltrexone, but bupropion may be a better fit for specific patients.
Direct answer (40-60 words)
Bupropion is an antidepressant that causes modest weight loss, averaging 2 to 5 kg at antidepressant doses (300 to 450 mg per day) over 6 to 12 months. Combined with naltrexone as the FDA-approved Contrave, the average weight loss is about 5 to 6% at one year. The mechanism involves dopamine and norepinephrine modulation that reduces appetite and food cravings.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The 30-second answer
- What bupropion is
- How bupropion produces weight loss (mechanism)
- The trial data on bupropion alone for weight loss
- Bupropion plus naltrexone (Contrave) for weight loss
- Dosing and titration
- Side effects and safety
- Who bupropion may be a good fit for
- Bupropion vs GLP-1 medications
- FAQ
- Sources
- Footer disclaimers
What bupropion is
Bupropion is an antidepressant first approved by the FDA in 1985 (originally as Wellbutrin) for major depressive disorder. It was later approved as Zyban for smoking cessation in 1997 and as a component of Contrave for chronic weight management in 2014.
Pharmacologically, it is a norepinephrine-dopamine reuptake inhibitor (NDRI). It blocks the reabsorption of two neurotransmitters, dopamine and norepinephrine, which raises their levels in synapses. This is different from SSRIs (selective serotonin reuptake inhibitors), which act primarily on serotonin.
The dopamine-norepinephrine action is what makes bupropion useful beyond depression. Dopamine is involved in food reward and addiction. Norepinephrine influences appetite and metabolic rate. By raising both, bupropion can reduce cravings and modestly suppress appetite.
Bupropion is available in three formulations:
| Form | Dosing | Typical use |
|---|---|---|
| Wellbutrin IR (immediate release) | 100 mg three times daily | Depression (rarely used now) |
| Wellbutrin SR (sustained release) | 150 mg twice daily | Depression, smoking cessation |
| Wellbutrin XL (extended release) | 150 mg or 300 mg once daily | Depression |
The Contrave combination uses a specialized sustained-release form of bupropion paired with low-dose naltrexone in a fixed-dose tablet.
How bupropion produces weight loss (mechanism)
The weight-loss mechanism is not fully understood but involves at least three pathways.
1. Hypothalamic appetite regulation. Bupropion activates POMC (pro-opiomelanocortin) neurons in the arcuate nucleus of the hypothalamus. These neurons release alpha-MSH, which signals satiety. The effect is modest on its own but amplified when combined with naltrexone (which removes a feedback brake on POMC neurons).
2. Dopamine and food reward. People with obesity often show altered dopamine signaling around food, similar in some ways to the patterns seen in addiction. By raising synaptic dopamine, bupropion may reduce the drive toward highly palatable, reward-driven eating. This is part of why bupropion helps with smoking cessation and binge-eating tendencies.
3. Norepinephrine and metabolic rate. Norepinephrine is involved in basal metabolic rate, lipolysis, and thermogenesis. Bupropion's modest stimulant-like effect can produce a small increase in calorie burn, though the contribution to total weight loss is limited.
The combined effect is reduced appetite, lower drive to snack between meals, and a small metabolic boost. The result is the 2 to 5 kg average weight loss seen in trials.
The trial data on bupropion alone for weight loss
Bupropion has been studied as a stand-alone weight-loss treatment in adults without depression. The data is consistent but modest.
Anderson et al., Obes Res 2002. 327 adults with obesity randomized to placebo, bupropion 300 mg, or bupropion 400 mg per day for 24 weeks. Weight loss:
- Placebo: 1.8% of body weight
- Bupropion 300 mg: 4.7%
- Bupropion 400 mg: 4.9%
About 13% of patients on bupropion 400 mg discontinued for adverse events, mostly insomnia.
Jain et al., Diabetes Obes Metab 2002. 422 adults with depression and obesity (overlapping conditions) followed for 24 weeks. Bupropion produced 4.6% weight loss versus 1.8% on placebo. Depression scores also improved.
Croft et al., J Clin Psychiatry 2002. Bupropion XL versus placebo over 44 weeks in adults with depression. Mean weight change favored bupropion by about 1.3 kg.
The pattern across trials: about 4 to 5% weight loss at antidepressant doses over 6 months. This is meaningful but smaller than the 5 to 22% seen with GLP-1 medications. The effect tends to plateau around 6 months.
For comparison, the FDA's standard for approving a weight-loss drug is at least 5% weight loss greater than placebo, sustained at one year. Bupropion alone hits this bar in some trials but not consistently, which is partly why it's not approved as a stand-alone weight-loss drug.
Bupropion plus naltrexone (Contrave) for weight loss
Contrave is the FDA-approved combination of sustained-release bupropion and low-dose naltrexone. It was approved in September 2014 for chronic weight management.
The rationale for combining them: bupropion activates POMC neurons. POMC neurons have a feedback mechanism using endogenous opioids (beta-endorphin) that limits how much they can fire. Naltrexone, an opioid receptor blocker, removes that brake, letting bupropion's effect build.
The two drugs alone produce small weight loss. Together they produce more.
The COR (Contrave Obesity Research) trials:
| Trial | Population | Weight loss at 56 weeks (Contrave vs placebo) |
|---|---|---|
| COR-I | Adults with obesity | 6.1% vs 1.3% (Greenway et al., Lancet 2010) |
| COR-II | Adults with obesity | 6.4% vs 1.2% (Apovian et al., Obesity 2013) |
| COR-BMOD | Adults plus intensive lifestyle intervention | 9.3% vs 5.1% (Wadden et al., Obesity 2011) |
| COR-Diabetes | Adults with T2DM | 5.0% vs 1.8% (Hollander et al., Diabetes Care 2013) |
The pattern: about 5 to 6 percentage points more weight loss than placebo at one year, with stronger effects when combined with intensive lifestyle counseling.
A 2016 cardiovascular outcomes trial (LIGHT) was terminated early after the FDA flagged concerns about premature data disclosure by the sponsor. The trial showed no signal of cardiovascular harm at the time of termination, and Contrave's label was not changed, but a definitive cardiovascular outcomes trial does not exist.
Dosing and titration
Bupropion is started low and increased over the first 4 weeks. The titration is partly to reduce side effects and partly to reduce seizure risk.
Bupropion XL for off-label weight loss (typical):
- Week 1-2: 150 mg once daily in the morning
- Week 3-4: 300 mg once daily in the morning (single 300 mg tablet)
- Week 5+: 300 mg once daily as maintenance
Some prescribers go higher to 450 mg daily (taken as 300 mg morning + 150 mg early afternoon), but seizure risk rises sharply at and above 450 mg per day.
Contrave (fixed-dose combination of bupropion 90 mg + naltrexone 8 mg per tablet):
- Week 1: 1 tablet in the morning
- Week 2: 1 tablet morning + 1 tablet evening
- Week 3: 2 tablets morning + 1 tablet evening
- Week 4 onward: 2 tablets morning + 2 tablets evening (maintenance, 360 mg bupropion + 32 mg naltrexone daily)
Take Contrave with food but avoid high-fat meals, which can increase blood levels and side effects. Do not crush or chew the tablets.
Side effects and safety
The most common side effects of bupropion (alone or in Contrave) at recommended doses:
| Side effect | Frequency at 300 mg | Frequency on Contrave |
|---|---|---|
| Insomnia | 11-19% | 13.7% |
| Dry mouth | 17-26% | 18.3% |
| Headache | 25% | 17.6% |
| Nausea | 9-13% | 32.5% |
| Constipation | 8-10% | 19.2% |
| Dizziness | 6-7% | 9.9% |
| Anxiety / agitation | 3-5% | 4.2% |
The Contrave numbers are higher for nausea because of the naltrexone component.
Serious risks:
- Seizure. The most important risk. At standard antidepressant doses (300 mg per day), the seizure incidence is about 0.1%, similar to other antidepressants. At 450 mg per day, it rises to about 0.4%. Above 450 mg, the rate climbs sharply. Bupropion is contraindicated in patients with a history of seizures, eating disorders (anorexia or bulimia), abrupt alcohol or benzodiazepine withdrawal, or use of MAO inhibitors within 14 days.
- Hypertension. Bupropion can modestly raise blood pressure. Patients with uncontrolled hypertension should stabilize before starting.
- Suicidal ideation. Antidepressants carry a class boxed warning for increased suicidal thoughts in patients under 25 during the first weeks of treatment.
- Activation of mania or psychosis. Rare but reported, especially in patients with bipolar disorder.
- Drug interactions. Bupropion strongly inhibits CYP2D6, which affects metabolism of many medications including certain SSRIs, antipsychotics, beta-blockers, and tamoxifen. Always provide a full medication list to your prescriber.
Who bupropion may be a good fit for
Bupropion (alone or as Contrave) makes the most sense for specific patient profiles.
Good fit:
- Adults with both depression and obesity. Bupropion treats both conditions and has a "weight neutral" reputation that makes it preferable to SSRIs (which often cause weight gain).
- Adults with strong food cravings or binge-eating tendencies, especially around highly palatable foods.
- Adults trying to quit smoking and lose weight at the same time.
- Adults with low energy, low motivation, or low libido on SSRIs (bupropion's profile is opposite).
- Adults who cannot tolerate or do not want injectable medication.
Less good fit:
- Adults with active or past seizure disorder.
- Adults with active eating disorder (anorexia, bulimia).
- Adults who drink heavily and are unwilling to reduce alcohol.
- Adults with poorly controlled hypertension.
- Adults expecting GLP-1-level weight loss.
- Adults with anxiety as the dominant symptom (bupropion can worsen anxiety in some).
Bupropion vs GLP-1 medications
Both produce weight loss but with very different magnitudes and mechanisms.
| Feature | Bupropion / Contrave | Semaglutide / Tirzepatide |
|---|---|---|
| Mean weight loss at one year | 4-6% | 13-22% |
| Route | Oral tablet | Weekly injection (Rybelsus is an oral exception) |
| Cost | $40-100/month for generic bupropion; ~$700/month for Contrave | $1,000-1,300/month brand name |
| FDA approval | Bupropion: depression, smoking. Contrave: weight management | Type 2 diabetes, obesity, OSA, CV risk |
| Common side effects | Insomnia, dry mouth, headache, nausea | Nausea, constipation, reflux |
| Mechanism | Dopamine + norepinephrine + opioid feedback | GLP-1 (and GIP) receptor agonism |
| Cardiovascular evidence | None definitive | SELECT (semaglutide): 20% MACE reduction |
For patients with severe obesity, GLP-1 medications produce substantially more weight loss. For patients with mild-to-moderate obesity, depression, smoking, or who don't want injections, bupropion-based therapy may be a better starting point.
Some practitioners combine the two when neither alone is sufficient, but combination GLP-1 plus bupropion-naltrexone is off-label and not formally studied. Always discuss combinations with the prescriber.
For deeper comparisons, see /articles/comparison/glp1-vs-other-weight-loss-medications/ and /articles/general-glp1/what-is-semaglutide/.
FAQ
Does bupropion cause weight loss?
Yes, modest weight loss in the range of 2 to 5 kg over 6 to 12 months at antidepressant doses (300 to 450 mg per day). It works partly by reducing appetite and partly by reducing food reward and cravings. The effect tends to plateau around 6 months.
How much weight can you lose on bupropion?
At 300 to 400 mg per day, average weight loss in trials is about 4 to 5% of body weight at 24 weeks. Combined with naltrexone (Contrave), average weight loss is about 5 to 6% at one year. Individual results range widely from no loss to over 10%.
Is bupropion FDA-approved for weight loss?
Bupropion alone is not FDA-approved for weight loss. Bupropion combined with naltrexone (the brand Contrave) is FDA-approved for chronic weight management in adults with BMI of 30 or higher, or BMI 27 or higher plus a weight-related condition.
How does bupropion compare to Ozempic for weight loss?
Ozempic (semaglutide) produces substantially more weight loss on average. In head-to-head settings, semaglutide produces 13 to 15% weight loss at one year compared with 4 to 6% for bupropion-naltrexone. The mechanisms are different, and the right choice depends on the patient.
Can you take bupropion with Ozempic or Wegovy?
Yes, the combination is sometimes used off-label when GLP-1 alone is not sufficient. There is no major drug interaction between bupropion and semaglutide or tirzepatide. The combination has not been formally studied in trials, so the safety and efficacy data is limited.
What dose of bupropion is best for weight loss?
The 300 mg per day dose has the best trade-off between efficacy and side effects in trials. The 400 to 450 mg dose produces slightly more weight loss but with higher seizure risk and more insomnia. Doses above 450 mg per day are not recommended for any indication.
How long does it take bupropion to cause weight loss?
Some appetite changes can be felt within 1 to 2 weeks. Measurable weight loss typically begins around weeks 4 to 6 and continues for about 6 months before plateauing. Maximum effect is usually reached by 6 to 12 months.
Is bupropion safer than GLP-1 medications?
Both have manageable safety profiles at recommended doses. Bupropion's main concern is seizure risk in predisposed patients. GLP-1 medications' main concerns are gastrointestinal side effects and rare pancreatitis or gallbladder issues. The right choice depends on individual risk factors.
Can bupropion cause weight gain?
Bupropion is one of the few antidepressants that does not typically cause weight gain. A small minority of patients gain weight on it, often in the context of treating depression that had previously suppressed appetite. The average effect is weight neutral to slight weight loss.
Does bupropion work for binge eating?
There is moderate evidence that bupropion reduces binge-eating behaviors, especially around highly palatable foods. The mechanism is the dopamine effect on reward-driven eating. Bupropion is not FDA-approved for binge eating disorder, but it is sometimes used off-label, especially in patients with co-occurring depression.
Can I drink alcohol on bupropion?
Heavy or binge drinking should be avoided. Alcohol lowers seizure threshold, and bupropion already does so. Light, occasional drinking (one drink occasionally) is usually tolerated, but the prescribing label recommends caution. Abrupt alcohol withdrawal also raises seizure risk and is a contraindication for starting bupropion.
Is Contrave the same as bupropion?
Contrave contains bupropion plus naltrexone in a fixed-dose combination tablet. Plain bupropion (Wellbutrin and generics) does not contain naltrexone. The naltrexone component is what makes Contrave specifically FDA-approved for weight management, and it produces somewhat more weight loss than bupropion alone.
Related guides
- TryLife Com Weight Loss: What the Platform Offers, How It Compares, and Whether Compounded GLP-1s Are the Right Choice
- Bupropion for Weight Loss: Dose, Mechanism, and How It Compares to GLP-1 Medications
- How Does Contrave Work? The Dual-Pathway Mechanism Behind Naltrexone-Bupropion Weight Loss
- Can Cider Vinegar Help With Weight Loss? A Realistic Look at the Trial Data, the Mechanism, and the Right Dose
- Is Cottage Cheese Good for Weight Loss? Yes, If You Buy the Right Tub
- What Is Compound Semaglutide? How It Works, Why It Exists, and Whether It's Right for You
Sources
- Anderson JW, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res. 2002;10:633-641.
- Jain AK, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049-1056.
- Croft H, et al. Effect on body weight of bupropion sustained-release in patients with major depression. J Clin Psychiatry. 2002;63:1009-1014.
- Greenway FL, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet. 2010;376:595-605.
- Apovian CM, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR (COR-II). Obesity. 2013;21:935-943.
- Wadden TA, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification (COR-BMOD). Obesity. 2011;19:110-120.
- Hollander P, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination on weight loss in patients with type 2 diabetes (COR-Diabetes). Diabetes Care. 2013;36:4022-4029.
- U.S. Food and Drug Administration. Contrave (naltrexone HCl/bupropion HCl) prescribing information. 2024 update.
- U.S. Food and Drug Administration. Wellbutrin XL (bupropion HCl extended-release) prescribing information. 2024 update.
- American College of Cardiology / American Heart Association. Obesity management guidelines. 2024.
- American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1).
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription medications to treat overweight and obesity. 2024.
Footer disclaimers
Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.
Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.
Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.
Trademark Notice. Wellbutrin and Zyban are registered trademarks of GlaxoSmithKline. Contrave is a registered trademark of Currax Pharmaceuticals. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →